Clinical Trial Search

Primary: Time-averaged Effect on Radiation Dermatitis Grade Measured With Common Terminology Criteria for Adverse Events (CTCAE, v 4.03) Following 3D Conformal Radiation Therapy…

Primary: Severity of Dermatitis in Radiation Treatment Site in Breast Cancer Patients — 2.6; 3.4 units on a scale — p=0.0077

Primary: Seroprotection, Non-Atopic Dermatitis (AD), Intradermal vs. Moderate to Severe Atopic Dermatitis, Intradermal - Influenza B — 34.4; 22.5 percentage of participants…

Primary: Achievement of 75% Reduction From Baseline in the Eczema Area and Severity Index (EASI 75 Response) at Week 12 (Day 84) — 32.3; 37.4 Percentage (%)

Primary: Mean Maximum Grade of Radiation Dermatitis by Treatment Arm. — 1.2; 1.3 Grade — p=0.18

Primary: Radiation Dermatitis — 34; 36 Participants — p=.8872

Primary: Percent of Women Who Develop Grade 3 or 4 Radiation Dermatitis (as Defined by the Stanford Radiation Dermatitis Scoring System) During a Course of Radiation Therapy — 6…

Primary: Incidence of Implant Failure — 8; 17; 34; 41 Number of Participants with Implant Fail

Primary: Number of Allergen-induced Eosinophils in the Skin — 11.95; 71.15 cells/mm2

Primary: Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy — 15; 15; 15; 15 participants

Primary: Percent Change in ISGA (Investigator's Static Global Assessment) Score — 67.8 percent change

Primary: Percentage of Patients With a Minimally Detected Decline (MDD) in Quality of Life (QOL) — 17; 18; 41; 19 percentage of patients

Primary: Overall Progression-Free Survival (PFS). — 370 Days

Primary: Late Radiation Toxicities at 2 Years From the Start of Radiation Treatment — 0 Participants

Primary: Cumulative Incidence (Estimated Percent of Participants) With Grade 3 or Higher Toxicity in Follow-up — 10.9 Percentage of patients